miR-27b attenuates dexamethasone-inhibited proliferation and osteoblastic differentiation in MC3T3-E1 cells by targeting PPARγ2

HUICHENG LV1*, TIEYI YANG1*, AMIN HE1, MINGBO WANG1, HAISHENG JIA1, MIN MA1 and SIQIN LI2

1Second Department of Trauma, Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010000; 2Department of Ultrasound Medicine, People’s Hospital of Inner Mongolia Autonomous Region, Hohhot, Inner Mongolia Autonomous Region 010020, P.R. China

Received August 7, 2020; Accepted July 13, 2021

DOI: 10.3892/etm.2021.11050

Abstract. Osteoporosis is a metabolic bone illness characterized by low bone density and a high risk of fracture. It is estimated that there are >60 million individuals in China suffering from this disease, which highlights an urgent requirement for the development of novel and safe drugs for the long-term treatment of osteoporosis. MicroRNAs (miRNAs/miRs) have previously been identified as critical regulators in the progression of osteoporosis. As an intronic miRNA, miR-27b enhances the osteoblastic differentiation of stem cells from the bone marrow and the maxillary sinus membrane. However, the mechanism underlying miR-27b in osteoporosis remains to be elucidated. In the present study, MC3T3-E1 pre-osteoblasts were treated with dexamethasone (DEX) to establish an in vitro model of osteoporosis. The results of the present study demonstrated that DEX treatment markedly inhibited the viability of MC3T3-E1 cells, and downregulated the expression level of miR-27b. The results of reverse transcription-quantitative PCR, western blotting and dual-luciferase assays revealed that miR-27b directly regulated and suppressed the expression of peroxisome proliferator-activated receptor γ2 (PPARγ2) in MC3T3-E1 cells. Furthermore, overexpression of miR-27b by transfection of cells with miR-27b mimic attenuated DEX-mediated inhibition of cell viability, alkaline phosphatase (ALP) activity and the expression levels of bone morphogenetic protein-2 (BMP2), runt-related protein 2 (Runx2) and osteocalcin (OCN). The results of the present study indicated that miR-27b alleviated DEX-inhibited proliferation and osteoblastic differentiation. Moreover, miR-27b knockdown repressed MC3T3-E1 cell viability, ALP activity and protein levels of BMP2, Runx2 and OCN. However, these effects were abrogated by small interfering RNA-mediated PPARγ2 silencing. In conclusion, the results of the present study demonstrated that miR-27b attenuated DEX-inhibited proliferation and osteoblastic differentiation in MC3T3-E1 pre-osteoblasts by targeting PPARγ2.

Introduction

Bone metabolism, including bone formation and resorption, is a continuous physiological process that regulates bone growth and remodeling (1). Mechanistically, bone formation is initialized by osteoblasts by synthesizing and secreting the main organic components of bone matrix, collagen and mucopolysaccharide (2). By contrast, osteoclasts trigger bone resorption by releasing proteinases to dissolve bone mineral and degrade bone matrix proteins (3). In healthy bone remodeling, bone formation and resorption are maintained in a dynamic balance. However, as the human body ages, the rate of bone formation decreases, disrupting the aforementioned balance, thus leading to the development of metabolic bone diseases such as osteoporosis (4).

Patients with osteoporosis exhibit decreased bone density and a high risk of fracture (5). In China, osteoporosis is a serious public health concern due to an increasing aging population (6). Previous studies have estimated that there are >60 million individuals in China suffering with osteoporosis (7,8). A number of medicines have been used to treat osteoporosis in the clinic; however, a number of potential side effects have been associated with these medicines that may impair the health of patients with osteoporosis during long-term treatment (9). Thus, further investigation into the development of novel, safe therapeutic strategies for the treatment of osteoporosis is required.
MicroRNAs (miRNAs/miRs) have been identified as critical regulators in the development of osteoporosis. Notably, miR-483-5p was found to be markedly upregulated and promoted osteoclast differentiation in patients with osteoporosis (10). Another study also investigated the role of miR-449b-5p in osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and found that miR-449b-5p could aggravate osteoporosis by inhibiting osteogenic differentiation through targeting of Satb2 (11). miR-27b is an intragenic miRNA located in the C9orf3 gene on chromosome 9 (12). miR-27b is involved in a number of biological processes, such as cell differentiation, proliferation and apoptosis, by inhibiting the expression of target genes post-transcriptionally (13-15). Previous studies revealed that miR-27b expression levels were abnormally downregulated during the formation of osteoclasts (16,17). Moreover, miR-27b regulated the osteogenesis of stem cells from bone marrow and the maxillary sinus membrane (18,19). Thus, we hypothesize that miR-27b may be implicated in the pathological process of osteoporosis.

Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated type II nuclear receptor that is mainly distributed in adipose tissue (20). As a critical transcription factor, PPARγ is implicated in a number of metabolic processes, such as fatty acid and glucose metabolism (21,22). In bone metabolism, PPARγ inhibits osteoblast formation and enhances osteoclastogenesis (23,24). A previous study demonstrated that PPARγ2, an isoform of PPARγ, is negatively regulated by miR-27b in chondrocytes (25). Thus, miR-27b may play a key role in the development of osteoporosis by targeting PPARγ2.

An increasing number of studies have suggested that osteoblast dysfunction disrupts the balance between bone resorption and bone formation by inhibiting osteoblast differentiation and proliferation, and enhancing osteoblast apoptosis in glucocorticoid-induced osteoporosis (26,27). Exposure to dexamethasone (DEX) induced the apoptosis of osteoblasts and in glucocorticoid-induced osteoporosis (26,27). Exposure to dexamethasone (DEX) induced the apoptosis of osteoblasts and in glucocorticoid-induced osteoporosis (26,27). Exposure to dexamethasone (DEX) induced the apoptosis of osteoblasts and in glucocorticoid-induced osteoporosis (26,27). Exposure to dexamethasone (DEX) induced the apoptosis of osteoblasts and in glucocorticoid-induced osteoporosis (26,27).

**Materials and methods**

**Cell culture and DEX treatment.** Mouse MC3T3-E1 pre-osteoblasts obtained from American Type Culture Collection (cat. no. CRL-2593) were cultured in DMEM (cat. no. SH30243.01; HyClone; Cytiva) containing 10% FBS (cat. no. 16000-044; Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin (cat. no. P1400; Beijing Solarbio Science & Technology Co., Ltd.) under 5% CO2 at 37˚C. Osteogenic differentiation was induced as described in a previous study (29). MC3T3-E1 pre-osteoblasts were treated with DEX to induce osteoporosis in vitro. The aim of the present study was to determine the function of the miR-27b/PPARγ axis in DEX-induced proliferation and osteoblastic differentiation in MC3T3-E1 cells.

**Cell transfection.** For overexpression or knockdown of miR-27b-3p, the miR-27b-3p mimic (5'-UUCAACUGGCU AAGUUCUGC-3'), miR-27b-3p inhibitor (5'-GCAGACUA GCCACUGUAA-3') and their corresponding negative controls (NCs) (NC-mimic, 5'-UGAUACUUGACUCGUC AGC-3'; and NC-inhibitor, 5'-CAGUACUUGAUAGUCAA CAA-3') were synthesized by Guangzhou RiboBio Co., Ltd. Three PPARγ2 small interfering (si)RNAs were designed to silence PPARγ2 expression and their sequences were as follows: siPPARγ2-1, 5'-CGCAUUCUUUGACUAACTT-3'; siPPARγ2-2, 5'-CAUGGUGUGUACUAACATTT-3'; and siPPARγ2-3, 5'-GGGGCAUCUGACAGGAAATT-3'. A scrambled siRNA was used as the corresponding NC (siNC, 5'-UUCUCCAGAAGGUGACGUTT-3'). MC3T3-E1 cells were trypsinized and suspended at a density of 1x10^6 cells/ml. A total of 2 ml cell suspension was inoculated into six-well plates overnight at 37˚C in a 5% CO2 incubator. When MC3T3-E1 cells reached a 60-70% confluence, cells were transfected with 5 µl mimic, inhibitor or siRNAs using Lipofectamine® 2000 (cat. no. 11668-019; Invitrogen; Thermo Fisher Scientific, Inc.) for 4-6 h at 37˚C. Following 24 h of transfection, serum-free transfer solution was replaced with complete medium, (DMEM with 10% FBS) and cells were cultured for a further 48 h.

**Alizarin red S (ARS) staining.** Following the induced osteogenic differentiation of MC3T3-E1 cells, osteogenic differentiation medium was discarded and the cells were washed three times with PBS. Cells were fixed with 4% paraformaldehyde for 30 min at 37°C in the dark, and subsequently stained with 100 µl CCK-8 solution (Signalway Antibody LLC) for 1 h. Cell viability was assessed by detecting the OD value at 460 nm.

**Alizarin red S (ARS) staining.** Following the induced osteogenic differentiation of MC3T3-E1 cells, osteogenic differentiation medium was discarded and the cells were washed three times with PBS. Cells were fixed with 4% paraformaldehyde for 30 min at 37°C in the dark, and subsequently stained with 1% ARS (Sigma-Aldrich; Merck KGaA) for 30 min at room temperature. Calcification nodules were observed, and images were captured using an inverted light microscope (magnification, x100).

**Receptor stimulation.** For overexpression or knockdown of miR-27b-3p, the miR-27b-3p mimic (5'-UUCAACUGGCU AAGUUCUGC-3'), miR-27b-3p inhibitor (5'-GCAGACUA GCCACUGUAA-3') and their corresponding negative controls (NCs) (NC-mimic, 5'-UGAUACUUGACUCGUC AGC-3'; and NC-inhibitor, 5'-CAGUACUUGAUAGUCAA CAA-3') were synthesized by Guangzhou RiboBio Co., Ltd. Three PPARγ2 small interfering (si)RNAs were designed to silence PPARγ2 expression and their sequences were as follows: siPPARγ2-1, 5'-CGCAUUCUUUGACUAACTT-3'; siPPARγ2-2, 5'-CAUGGUGUGUACUAACATTT-3'; and siPPARγ2-3, 5'-GGGGCAUCUGACAGGAAATT-3'. A scrambled siRNA was used as the corresponding NC (siNC, 5'-UUCUCCAGAAGGUGACGUTT-3'). MC3T3-E1 cells were trypsinized and suspended at a density of 1x10^6 cells/ml. A total of 2 ml cell suspension was inoculated into six-well plates overnight at 37˚C in a 5% CO2 incubator. When MC3T3-E1 cells reached a 60-70% confluence, cells were transfected with 5 µl mimic, inhibitor or siRNAs using Lipofectamine® 2000 (cat. no. 11668-019; Invitrogen; Thermo Fisher Scientific, Inc.) for 4-6 h at 37˚C. Following 24 h of transfection, serum-free transfer solution was replaced with complete medium, (DMEM with 10% FBS) and cells were cultured for a further 48 h.

**Cell Counting Kit-8 (CCK-8) assay.** MC3T3-E1 cells were re-suspended in PBS at a density of 2x10^4 cells/ml for 1 min at 37°C. A total of 100 µl suspension was added into a 96-well plate and cultured overnight at 37°C. Following 0, 12, 24 or 48 h of treatment as aforementioned, cells were treated with 100 µl CCK-8 solution (Signalway Antibody LLC) for 1 h. Cell viability was assessed by detecting the OD value at 460 nm.
amplified using the SYBR Green qPCR Master mix (cat. no. K0223; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The following thermocycling conditions were used for qPCR: 95°C for 10 min; followed by 40 cycles at 95°C for 15 sec and 60°C for 45 sec; final extension at 95°C for 15 sec, 60°C for 1 min, 95°C for 15 sec and 60°C for 15 sec. U6 and GAPDH were used as internal controls, and the relative levels of miR-27b and PPARγ2 mRNA were calculated using the 2^ΔΔCq method (10). The primer sequences were as follows: miR-27b-3p forward, 5'-GCGCGTTCACAGTGGCCAGCAGGCGCTTCACG-3' and reverse, 5'-AGTGCAAGGTCGGAGTGATTG-3'; U6 forward, 5'-GCTTCGGCAGCACACGTTC-3' and reverse, 5'-GGAA CGCTTTACAG-3'; PPARγ2 forward, 5'-TGGGATGTTGATGTTGATGTTG-3' and reverse, 5'-AAGCCCAGAACATCATCC-3'; and GAPDH forward, 5'-CTGCCCCAGAACATCATCC-3' and reverse, 5'-TCAGATGTCGTTTAC-3'.

Western blotting. Target proteins were extracted from MC3T3-E1 cells using RIPA lysis buffer (Jrdun Biotechnology) and the protein concentration was determined by a bicinchoninic acid assay kit (Thermo Fisher Scientific, Inc.) following manufacturer's protocol. The isolated proteins (25 µg/lane) were separated by electrophoresis in 10% SDS-polyacrylamide gels, and transferred onto a PVDF membrane. Membranes were subsequently blocked with 5% non-fat milk overnight at 4°C, and incubated with the following primary antibodies: Anti-PPARγ2 (1:500; cat. no. ab45036; Abcam), anti-bone morphogenetic protein-2 (BMP2; 1:1,000; cat. no. orb334018; Biorbyt, Ltd.), anti-runt-related protein 2 (Runx2; 1:1,000; cat. no. ab23981; Abcam), anti-osteocalcin (OCN; 1:1,000; cat. no. ab93876; Abcam) and anti-GAPDH (1:2,000; cat. no. 5174; CST Biological Reagents Co., Ltd.) overnight at 4°C. Following primary incubation, membranes were incubated with the horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (Beyotime Institute of Biotechnology; cat. nos. A0208 and A0216; both 1:1,000) at 37°C for 1 h. Signal quantification was performed by an enhanced chemiluminescence system (Bio-Rad Laboratories, Inc.). The bands were quantified by densitometry with ImageJ software (version 1.51; National Institutes of Health).

Dual-luciferase reporter assay. Bioinformatics software TargetScan 7.2 (targetscan.org/vert_72/) was used to predict target genes of miR-27b, and the results revealed the binding sites between miR-27b and PPARγ2. Wild-type (wt) or mutant (mut) PPARγ2-3' untranslated regions (UTRs) were cloned into a pGL3-Promoter plasmid containing the firefly luciferase gene (Promega Corporation). The reconstructed pGL3-Promoter was introduced into the MC3T3-E1 pre-osteoblasts along with the pRL-TK-Renilla reporter (Promega Corporation) using Lipofectamine® 3000 reagent (Thermo Fisher Scientific, Inc.) following manufacturer's protocol for 4-6 h at 37°C. Following 6 h of transfection, cells were treated with the miR-27b mimic. After 24 h, luciferase activity was assessed using a Dual-Promoter Luciferase Assay kit (cat. no. E1910; Promega Corporation).

Biochemical detection. Following treatment aforementioned, the supernatant of MC3T3-E1 pre-osteoblasts was obtained by centrifugation at 800 x g for 10 min at 4°C, and ALP activity was determined using an ALP kit (cat. no. A059-2; Nanjing Jiancheng Bioengineering Institute). The supernatant and kit solution were mixed and incubated in a water bath for 15 min at 37°C, according to the manufacturer's protocol. The absorbance value was measured at 520 nm.

Statistical analysis. Quantitative analysis was conducted using GraphPad Prism 7.0 (GraphPad Software, Inc.) and each experiment was repeated three independent times. Data are presented as the mean ± standard deviation. The difference between groups was analyzed using an unpaired t-test, two-way ANOVA followed by Bonferroni's multiple comparisons test or one-way ANOVA followed by Tukey's multiple comparisons test. P<0.05 was considered to indicate a statistically significant difference.

Results

DEX treatment significantly reduces cell viability and miR-27b expression levels in MC3T3-E1 pre-osteoblasts. MC3T3-E1 pre-osteoblasts were cultured with 1 μM DEX, and cell viability was detected at 0, 12, 24 and 48 h after treatment. The results demonstrated that DEX treatment markedly inhibited the viability of MC3T3-E1 cells at 24 and 48 h compared with DMSO (Fig. 1A). In addition, the miR-27b level was also measured, and DEX treatment significantly downregulated the expression level of miR-27b at 12, 24 and 48 h compared with 0 h (Fig. 1B).
miR-27b directly regulates PPARγ2. The results of the TargetScan bioinformatics analysis revealed that PPARγ2 was predicted to be a potential target of miR-27b. To verify this interaction, the miR-27b mimic and inhibitor were transfected into MC3T3-E1 pre-osteoblasts. The results indicated that the expression level of miR-27b was markedly upregulated by the miR-27b mimic and significantly downregulated by the miR-27b inhibitor compared with its corresponding NC (Fig. 2A). Furthermore, PPARγ2 mRNA and protein expression was repressed by the miR-27b mimic and significantly enhanced by the miR-27b inhibitor compared with its corresponding NC (Fig. 2B and C). MC3T3-E1 pre-osteoblasts were co-transfected with the miR-27b mimic and luciferase vector containing wt or mut PPARγ2-3'UTR. Relative luciferase activity was assessed by the dual-luciferase assay. ***P<0.001 vs. NC-mimic, NC-inhibitor or NC-mimic + wt. miR, microRNA; NC, negative control; PPARγ2, peroxisome proliferator-activated receptor γ2; wt, wild-type; mut, mutant; UTR, untranslated region.

miR-27b overexpression attenuates DEX-inhibited proliferation and osteoblastic differentiation in MC3T3-E1 pre-osteoblasts. The potential functions of miR-27b were observed following transfection of the miR-27b mimic in DEX-treated MC3T3-E1 cells. The results of the present study demonstrated that miR-27b overexpression partly reversed DEX-inhibited miR-27b expression and cell proliferation (Fig. 3A and B). The ARS and ALP staining of M3T3-E1 cells revealed that DEX markedly inhibited osteoblastic differentiation compared with DMSO plus NC-mimic group, while DEX-mediated effects were abrogated by the miR-27b mimic (Fig. 3C and D). In addition, the ALP activity, and the expression levels of BMP2, Runx2 and OCN were investigated as hallmarks of osteoblastic differentiation. The results of the present study demonstrated that DEX treatment significantly decreased the ALP activity and protein expression levels of BMP2, Runx2 and OCN, but increased PPARγ2 protein expression levels compared with DMSO plus NC-mimic group. Furthermore, DEX-mediated effects were abrogated by the miR-27b mimic (Fig. 3E-G). These results suggested that miR-27b overexpression attenuated DEX-inhibited osteoblastic differentiation.

Inhibition of miR-27b suppresses proliferation and osteoblastic differentiation in MC3T3-E1 pre-osteoblasts by upregulation of PPARγ2. The transfection efficiency of siRNAs targeting PPARγ2 in MC3T3-E1 cells was demonstrated by
RT-qPCR and western blot analysis, with the lowest mRNA and protein expression detected in cells transfected with siPPARγ2-2. siPPARγ2-2 was therefore selected for subsequent analyses (Fig. 4A and B). To investigate the potential regulation of PPARγ2 by miR-27b, MC3T3-E1 pre-osteoblasts were co-transfected with the miR-27b inhibitor and PPARγ2 siRNA. The results of the present study indicated that miR-27b knockdown significantly increased PPARγ2 expression, and decreased cell viability, osteoblastic differentiation, ALP activity and the expression level of BMP2, Runx2 and OCN. However, these effects were abrogated by siPPARγ2-2 transfection (Fig. 4C-H). Thus, miR-27b knockdown inhibited proliferation and osteoblastic differentiation in MC3T3-E1 pre-osteoblasts by the upregulation of PPARγ2.

**Discussion**

miRNAs are a type of non-coding RNA that function by inhibiting the expression of downstream target genes (30). A previous study has demonstrated that miRNAs are critical regulators during the formation, viability and death of osteoblasts and osteoclasts (31). A number of miRNAs, such as miR-7b-5p and miR-19a-3p, alleviate the progression of osteoporosis (32,33). Thus, a number of miRNAs may act as novel targets for the development of safe and effective osteoporosis treatment options.

Individuals develop osteoporosis due to decreased viability and function of osteoblasts caused by glucocorticoid treatment (26). In the present study, DEX treatment significantly decreased cell viability, ALP activity and osteoblastic differentiation of mouse MC3T3-E1 pre-osteoblasts, indicating the successful establishment of an osteoporosis model induced by DEX. miR-27b is an intragenic miRNA involved in a number of diseases. For example, miR-27b suppresses cancer cell proliferation and enhances apoptosis in neuroblastoma, bladder and gastric cancer (15,34,35). In cardiac disease, adenoviral vector encoding sense miR-27b overexpression causes cardiac hypertrophy and fibrosis (36,37). In osteoarthritis, miR-27b decreases the degradation of the extracellular matrix in chondrocytes (38). However, the exact pathological mechanisms underlying miR-27b in osteoporosis remain to be elucidated. The results of previous studies demonstrated that miR-27b inhibited osteogenesis in maxillary sinus membrane stem cells, and promoted osteoblastic differentiation in BMSCs (18,19). These results suggested that the effect of miR-27b on osteogenesis depends on the cell type. The results of the present study revealed that miR-27b knockdown repressed proliferation and osteoblastic differentiation in MC3T3-E1 pre-osteoblasts, which is consistent with the findings by Seenprachawong et al (18) that miR-27b promotes osteogenesis in human MSCs. Moreover, miR-27b overexpression attenuated DEX-inhibited proliferation and osteoblastic differentiation, highlighting the potential protective role of miR-27b in osteoporosis. However, the decreased cell viability and osteoblastic differentiation in MC3T3-E1 pre-osteoblasts induced by DEX were not reversed by miR-27b. Previous
studies have reported that a number of other miRNAs, such as miR-365 (39), miR-199a (40), let-7f-5p (41) and miR-216a (42), play roles in the function of DEX in osteoporosis. PPARγ, a member of the nuclear receptor family, regulates the transcription of target genes by binding to the specific PPAR response element (43). Previous studies have reported that PPARγ is directly regulated by miR-27b in a number of cell lines, including adipocytes, neuroblastoma cells and BMSCs (18,34,44). An isoform of PPARγ, PPARγ2, is the target of miR-27b in chondrocytes (25). Consistent with the findings of previous studies, the results of the present study revealed the regulatory effect of miR-27b on PPARγ2 in MC3T3-E1 cells. A previous study has revealed that PPARγ2 inhibits osteoblastogenesis and enhances adipogenesis (45). The results of the present study revealed that miR-27b enhanced proliferation and osteoblastic differentiation in MC3T3-E1 cells by targeting PPARγ2, highlighting the importance of PPARγ2 in the formation of osteoblasts.
miR-27b-3p inhibits proliferation and osteoblastic differentiation in MC3T3-E1 cells.

In conclusion, the results of the present study demonstrated that miR-27b alleviated DEX-inhibited proliferation and differentiation in MC3T3-E1 pre-osteoblasts. Therefore, miR-27b may act as a potential target for the treatment of osteoporosis. Further *in vitro* experiments and clinical practice are required to explore the potential role of miR-27b in osteoporosis.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Inner Mongolia Natural Science Foundation (grant no. 2017MS08118) and the Inner Mongolia Medical University 'Science and Technology Million Project' (grant no. YKD2016kjw010).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

SL and HL designed this study. TY and MW performed the experiments. AH, HJ and MM analyzed and interpreted the data. TY and SL confirm the authenticity of all the raw data. HL, TY and SL wrote the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Gaffney-Stomberg E: The impact of trace minerals on bone metabolism. Biol Trace Elem Res 188: 26-34, 2019.
2. Kini U and Nandeesh B: Physiology of bone formation, remodeling, and metabolism. In: Radionucleide and Hybrid Bone Imaging. Fogelman I, Gnanasegaran G and van der Wall H (eds). Springer, Berlin, Heidelberg, pp29-57, 2012.
3. Strålberg F, Kassem A, Kasprzykowski F, Abrahamsson M, Grubb A, Lindholm C and Lerner UH: Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cytoine proteinase inhibitors. J Leukoc Biol 101: 1233-1243, 2017.
4. Demontiero O, Vidal C and Duque G: Aging and bone loss: New insights for the clinician. Ther Adv Musculoskelet Dis 4: 61-76, 2012.
5. Jiang N and Xia W: Assessment of bone quality in patients with diabetes mellitus. Osteoporos Int 29: 1721-1736, 2018.
6. Lin X, Xiong D, Peng YQ, Sheng ZF, Wu XY, Wu XP, Wu F, Yuan LQ and Liao EY: Epidemiology and management of osteoporosis in the People's Republic of China: Current perspectives. Clin Interv Aging 10: 1017-1033, 2015.
7. Zeng Q, Li N, Wang Q, Feng J, Sun D, Zhang Q, Huang J, Wen Q, Hu R, Wang L, et al: The prevalence of osteoporosis in China, a nationwide, multicenter DXA survey. J Bone Miner Res 34: 1789-1797, 2019.
8. Cui Z, Meng X, Feng H, Zhang S, Liu Z, Zhu T, Ye K, Xing Y, Sun C, Zhou F, et al: Estimation and projection about the standardized prevalence of osteoporosis in mainland China. Arch Osteoporos 15: 2, 2019.
9. Skjoldt MK, Frost M and Abrahamsen B: Side effects of drugs for osteoporosis and metastatic bone disease. Br J Clin Pharmacol 85: 1063-1071, 2019.
10. Li K, Chen S, Cai P, Chen K, Li L, Yang X, Yi J, Luo X, Du Y and Zheng H: miRNA-483-5p is involved in the pathogenesis of osteoporosis by promoting osteoclast differentiation. Mol Cell Probes 49: 10479, 2020.
11. Li JY, Wei X, Sun Q, Zhao XQ, Zheng CY, Bai CX, Du J, Zhang Z, Zhu LG and Jia YS: MicroRNA-449b-5p promotes the progression of osteoporosis by inhibiting osteogenic differentiation of BMSCs via targeting Sirt6. Eur Rev Med Pharmacol Sci 23: 6394-6403, 2019.
12. Kida K, Nakajima M, Mohri T, Oda Y, Takagi S, Fukumi T and Yoko T: PPARγ is regulated by miR-21 and miR-27b in human liver. Pharm Res 28: 2467-2476, 2011.
13. Chen D, Si W, Shen J, Du C, Lou W, Bao C, Zheng H, Pan J, Zhong G, Xu L, et al: miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells. Cell Death Dis 9: 188, 2018.
14. Henriksen TI, Davidsen PK, Pedersen M, Schultz HS, Hansen SM, Larsen TJ, Vaag A, Pedersen BK, Nielsen S and Scheele C: Dysregulation of a novel miR-213b/27b-p53 axis impairs muscle stem cell differentiation of humans with type 2 diabetes. Mol Metab 6: 770-779, 2017.
15. Wu X, Yan T, Wang Z, Wu X, Cao G and Zhang C: lncRNA ZEB2-AS1 promotes bladder cancer cell proliferation and inhibits apoptosis by regulating miR-27b. Biomed Pharmacother 96: 299-304, 2017.
16. Han Z, Zhan R, Chen S, Deng J, Shi J and Wang W: miR-328b1/Oncostatin m axis inhibits prostate cancer bone metastasis via modulating osteoclast differentiation. J Cell Biochem 121: 1664-1674, 2020.
17. Takigawa S, Chen A, Wan Q, Na S, Sudo A, Yokota H and Hamamura K: Role of miR-222-3p in c-Src-Mediated Regulation of Osteoclastogenesis. Int J Mol Sci 17: 240, 2016.
18. Seenprachawong K, Tawornsawutruk T, Nantasenamat C, Nuchnoi P, Hongeng S and Supokawej A: miR-130a and miR-27b enhance osteogenesis in human bone marrow mesenchymal stem cells via specific down-regulation of peroxisome proliferator-activated receptor γ. Front Genet 9: 543, 2018.
19. Peng W, Zhu S, Li X, Weng J and Chen S: miR-27b-3p suppressed osteogenic differentiation of maxillary sinus membrane stem cells by targeting Sp7. Implant Dent 26: 492-499, 2017.
20. Guo M, Li C, Lei Y, Xu S, Zhao D and Lu XY: Role of the adipose PPARα-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors. Mol Psychiatry 22: 1056-1068, 2017.
21. Calvier L, Chouvarine P, Legchenko E, Hoffmann N, Geldner J, Borchart P, Jonigk D, Mozes MM and Hansmann G: PPAR-y links BMP2 and TGFβ1 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism. Cell Metab 25: 1118-1134, e1117, 2017.

22. Ye G, Gao H, Wang Z, Lin Y, Liao X, Zhang H, Chi Y, Zhu H and Dong S: PPARα and PPARγ activation attenuates total free fatty acid and triglyceride accumulation in macrophages via the inhibition of Fatp1 expression. Cell Death Dis 10: 39, 2019.

23. Wang Y, Chong L-W and Evans RM: PPAR-γ regulates osteocalcogen in mice. Nat Med 13: 1496-1503, 2007.

24. Zhuang H, Zhang X, Zhu C, Tang X, Yu F, Shang GW and Cai X: Molecular mechanisms of PPAR-γ governing MSC osteogenic and adipogenic differentiation. Curr Stem Cell Res Ther 11: 255-264, 2016.

25. Xu J, Lv S, Hou Y, Xu K, Sun D, Zheng Y, Zhang Z, Li X, Li Y and Chi G: miR-27b promotes type II collagen expression by targeting peroxisome proliferator-activated receptor-γ2 during rat articular chondrocyte differentiation. Biosci Rep 38: BSR20171109, 2018.

26. Xu WN, Zheng HL, Yang RZ, Jiang LS and Jiang SD: HIF-1α Regulates Glucocorticoid-Induced Osteoporosis Through PDK1/AKT/mTOR Signaling Pathway. Front Endocrinol (Lausanne) 10: 922, 2020.

27. Li P, Mao WW, Zhang S, Zhang L, Chen ZR and Lu ZD: Sodium hydrosulfide alleviates dexamethasone-induced cell senescence and dysfunction through targeting the miR-22/sirt1 pathway in osteoblastic MC3T3-E1 cells. Exp Ther Med 21: 238, 2021.

28. Yang L, Lai S, Mu S, Guo R, Zhou L and Fa Q: Paconiflorin Attenuates Dexamethasone-Induced Apoptosis of Osteoblast Cells and Promotes Bone Formation via Regulating AKT/mTOR/Autophagy Signaling Pathway. Evid Based Complement Alternat Med 2021: 6623464, 2021.

29. Zhu C, Zheng XF, Yang YH, Li B, Wang YR, Jiang SD and Jiang LS: LGR4 acts as a key receptor for R-spondin 2 to promote osteogenesis through Wnt signaling pathway. Cell Signal 28: 989-1000, 2016.

30. Gulyaeva LF and Kushlinskiy NE: Regulatory mechanisms of microRNA expression. J Transl Med 14: 143, 2016.

31. Ge DW, Wang WW, Chen HT, Yang L and Cao XJ: Functions of microRNAs in osteoporosis. Eur Rev Med Pharmacol Sci 21: 4784-4789, 2017.

32. Chen R, Qu H, Tong Y, Liao F, Hu X, Qiu Y and Liao Y: miRNA-19a-3p alleviates the progression of osteoporosis by targeting HDAC4 to promote the osteogenic differentiation of hMSCs. Biochem Biophys Res Commun 516: 666-672, 2019.

33. Li QQ, Wei Q, Zhai XC, Qin L, Li HB, Meng R and Chen SC: miRNA-7b-5p attenuates the progression of osteoporosis by inhibiting adipose differentiation of hMSCs via regulating IRS2. Eur Rev Med Pharmacol Sci 23: 9207-9214, 2019.

34. Lee JJ, Drakaki A, Ilipoulous D and Struhl K: miR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 31: 3818-3825, 2012.

35. Tao J, Zhi X, Zhang X, Fu M, Huang H, Fan Y, Guan W and Zou C: miR-27β-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer. J Exp Clin Cancer Res 34: 139, 2015.

36. Wang J, Song Y, Zhang Y, Xiao H, Sun Q, Hou N, Guo S, Wang Y, Fan K, Zhan D, et al: Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res 22: 516-527, 2012.

37. Hou N, Wang J, Li Z, Cao Y, Fan K and Yang X: Cardiomyocyte overexpression of miR-27b resulted in cardiac fibrosis and mitochondria injury in mice. Yi Chuan 34: 326-334, 2012 (In Chinese).

38. Li YF, Li SH, Liu Y and Luo Y: Long noncoding RNA CIR promotes chondrocyte extracellular matrix degradation in osteoarthritis by acting as a sponge for Mir-27b. Cell Physiol Biochem 43: 602-610, 2017.

39. Xu D, Gao Y, Hu N, Wu L and Chen Q: miR-365 Ameliorates Dexamethasone-Induced Suppression of Osteogenesis in MC3T3-E1 Cells by Targeting HDAC4. Int J Mol Sci 18: 977, 2017.

40. Tang J, Yu H, Wang Y, Duan G, Wang B, Li W and Zhu Z: MicroRNA-199a counteracts glucocorticoid inhibition of bone marrow mesenchymal stem cell osteogenic differentiation through regulation of Klotho expression in vitro. Cell Biol Int 44: 2532-2540, 2020.

41. Shen GY, Ren H, Shang Q, Zhao WH, Zhang ZD, Yu X, Huang JJ, Tang JJ, Yang ZD, Liang D, et al: Let-7i-5p regulates TGFBR1 in glucocorticoid-inhibited osteoblast differentiation and ameliorates glucocorticoid-induced bone loss. Int J Biol Sci 15: 2182-2197, 2019.

42. Li H, Li T, Fan J, Li T, Fan L, Wang S, Weng X, Han Q and Zhao RC: miR-216a rescues dexamethasone suppression of osteogenesis, promotes osteoblast differentiation and enhances bone formation, by regulating c-Cbl-mediated PI3K/AKT pathway. Cell Death Differ 22: 1935-1945, 2015.

43. Corrales P, Izquierdo-Lahuerta A and Medina-Gómez G: Maintenance of kidney metabolic homeostasis by PPAR gamma. Int J Mol Sci 19: 2063, 2018.

44. Karbiener M, Fischer C, Nowitsch S, Oppriernig P, Papak C, Ailhaud G, Dani C, Amri EZ and Scheideler M: MicroRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma. Biochem Biophys Res Commun 390: 247-251, 2009.

45. Shockey KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA and Lecka-Czernik B: PPARγamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 106: 232-246, 2009.

46. Guo L, Chen K, Yuan J, Huang P, Xu X, Li C, Qian N, Qi J, Shao Z, Deng L, et al: Estrogen inhibits osteoclasts formation and bone resorption via microRNA-27a targeting PPARγ and APC. J Cell Physiol 234: 581-594, 2018.

47. Patel JJ, Butters OR and Arnett TR: PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. Cell Biochem Funct 32: 368-377, 2014.

48. Wang H and Shen Y: MicroRNA 20a negatively regulates the growth and osteoclastogenesis of THP 1 cells by downregulating PPARγ. Mol Med Rep 20: 4271-4276, 2019.

49. Wang Y, Pan Z and Chen F: Inhibition of PPARγ by bisphenol A diglycidyl ether ameliorates dexamethasone-induced osteoporosis in a mouse model. J Int Med Res 47: 6268-6277, 2019.